Delving into the Latest Updates on TZ-050 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Tizona Therapeutics, Inc.Startup

Active Organization-

Inactive Organization

Tizona Therapeutics, Inc.Startup

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

TBA is an herbicide in general low acute toxicity and placed into a third category of toxicity. The aim of this study was to determine the effect of TBA and its formulation Radazin TZ-50 in doses of ADI values and 1/100 LD 50 on haematological and biochemical blood parameters in mice. The number of leukocytes was significantly decreased (p < 0.05) in all treated groups compared to non-treated mice (8.81 ± 3.23 × 10(9)/L). The lowest value 3.90 ± 0.74 × 10(9)/L was observed in group treated with TBA (1/100 LD 50) followed by TBA (ADI) 4.49 ± 0.98 × 10(9)/L, Radazin TZ-50 (1/100 LD 50) 4.67 ± 1.24 × 10(9)/L and Radazin TZ-50 (ADI) 4.73 ± 1.15 × 10(9)/L. The values of the enzyme AST was increased from 190.00 ± 26.46-270.00 ± 147.30 U/L in serum of all treated groups as compared to non-treated mice (110.00 ± 20.00). LDH values showed significant increase (3236.67 ± 56.86-4054.33.5 ± 837.16 U/L) as compared to non-treated mice (1010.00 ± 222.71 U/L). Total protein value was significantly (p < 0.05) increased in TBA 1/100 LD50 (63.00 ± 7.48 g/L) and Radazin TZ-50 1/100 LD50 (60.00 ± 2.00 g/L) compared to non-treated mice 52.00 ± 4.00 g/L. Increased serum concentrations of urea and creatinine obtained in mice treated with TBA and Radazin TZ-50 indicates a greater degree of dysfunction of the nephron. TBA and its formulation of Radazin TZ-50 in applied doses demonstrate changes in the number of leukocytes and limited hepatotoxic effects.

100 Deals associated with TZ-050

Login to view more data